All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Trial is partly outside EEC, and reported results | 2004-001346-33 | A Phase 3 Double-Blind Randomised, Placebo-Controlled Study of the safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2to <18) with Chronic Hepatitis B | bad-data | |
| Reported results | 2004-002254-59 | A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combi... | 2007-06-25 | due-trials |
| Completed, but no date, and reported results | 2004-003745-40 | Phase II pilot study on safety of administration of 3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment ( day 50-8th W... | bad-data | |
| Reported results | 2004-005083-25 | A Phase IV, Randomized, Double-Blind, Placebo-Controlled Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV 1 Seronegative Healthy Adult Males | 2007-11-09 | due-trials |
| Reported results | 2004-005119-27 | A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B | 2016-01-19 | due-trials |
| Reported results | 2004-005120-41 | A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B | 2016-01-28 | due-trials |
| Reported results | 2005-003136-22 | A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combinatio... | 2010-10-05 | due-trials |
| Reported results | 2005-004096-37 | A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B... | 2012-04-12 | due-trials |
| Reported results Terminated | 2005-004495-21 | Pilot study on safety of four weekly administrations of 7 mg/kg of liposomal amphotericin B (AmBisome®) in antifungal primary prophylaxis treatment of elderly patients with acute lymphoblastic leukemi... | 2007-08-17 | due-trials |
| Reported results | 2005-004654-28 | Phase IV, multicenter, randomized, open-label pilot study of Truvada or Emtricitabine alone versus HAART interruption in HIV-infected patients who need to interrupt HAART and who are infected with HIV... | 2008-12-03 | due-trials |
| Reported results | 2005-005786-11 | Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from AZT containing backbone to Truvada in HIV-1-in... | 2008-09-16 | due-trials |
| Reported results | 2006-001898-25 | DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy ... | 2009-01-16 | due-trials |
| Reported results | 2006-001899-20 | DORADO-EX A Dose-Blinded, Long Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension | 2010-02-18 | due-trials |
| Reported results | 2006-003547-23 | DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group S... | 2009-08-19 | due-trials |
| Reported results | 2006-003548-42 | DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension A Double-Blind, Active-Con... | 2010-03-19 | due-trials |
| Reported results | 2006-004714-40 | A Randomized, Double Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B | 2012-08-10 | due-trials |
| Completed, but no date, and reported results | 2007-000607-15 | Phase II pilot multicenter study on efficacy and safety of liposomal amphotericin B (AmBisome) at 2 mg/kg/day in the treatment of candidemia and invasive candidiasis in nonneutropenic patients | bad-data | |
| Reported results | 2007-001601-16 | A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects with C... | 2009-03-31 | due-trials |
| Reported results | 2007-003354-28 | A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching from a Stable HAART Regimen of fixed dose Abacavir/Lamivuidine (Kivexa) Plus Efavirenz, to Once D... | 2010-01-12 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-003418-32 | A Phase III, Randomised, Open- Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate versus Continuing Stavudine or Zidovudine in Virologi... | 2009-03-06 | bad-data |
| Trial is partly outside EEC, and reported results | 2007-003704-35 | A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection | 2015-12-02 | bad-data |
| Reported results | 2007-004225-26 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background R... | 2015-04-28 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-004277-26 | An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebuliser Solution (AZLI) versus Tobramycin Nebuliser Solution (TNS) in an Interm... | 2010-11-22 | bad-data |
| Trial is outside EEC, and reported results | 2007-004736-23 | A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subject... | bad-data | |
| Reported results | 2007-005769-36 | A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovir D... | 2010-12-20 | due-trials |
| Reported results | 2008-001464-36 | A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofov... | 2015-02-09 | due-trials |
| Reported results | 2008-002043-16 | A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of fixed dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kalet... | 2009-10-19 | due-trials |
| Exempt, with results | 2008-002045-23 | A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects. | 2008-10-28 | not-yet-due |
| Reported results | 2008-002361-31 | A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults with Non-Alcoholic Steatohepat... | 2009-08-05 | due-trials |
| Reported results Terminated | 2008-003839-20 | A Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 µg Regadenoson Bolus for Pharmacological Stress Echocardiography | 2010-06-04 | due-trials |
| Reported results | 2008-003917-29 | A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents | 2010-07-02 | due-trials |
| Reported results | 2008-004405-34 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary... | 2011-02-28 | due-trials |
| Reported results | 2008-004527-31 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ri... | 2013-09-05 | due-trials |
| Reported results Terminated | 2008-007455-26 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension | 2012-01-05 | due-trials |
| Reported results | 2008-007456-96 | A Phase 2b, Double blind, Randomized, Parallel Group, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults with Chronic Hepatitis C Virus Infection | 2010-07-20 | due-trials |
| Reported results Terminated | 2009-011169-98 | A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmon... | 2011-01-06 | due-trials |
| Trial is outside EEC, and reported results | 2009-011740-19 | Phase 3b Randomized, Double-Blind, Placebo-Controlled Two-Part Trial to Assess the Safety and Efficacy of Continuous Aztreonam for Inhalation Solution (AZLI) in Subjects with Cystic Fibrosis (CF) and ... | bad-data | |
| Reported results | 2009-013442-86 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with... | 2010-12-31 | due-trials |
| Reported results | 2009-013690-18 | A Phase 2, Randomized, Open-Label trial of GS-9256 plus GS-9190 alone and in combination with Ribavirin for 28 days in Treatment Naive Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. | 2012-01-30 | due-trials |
| Reported results | 2009-016758-42 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine... | 2014-10-28 | due-trials |
| Reported results | 2009-016759-22 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoprox... | 2015-04-17 | due-trials |
| Reported results | 2009-017168-17 | A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction | 2011-02-08 | due-trials |
| Reported results | 2010-019562-91 | A Phase 3, Double-Blind, Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome) for the Prevention of Inv... | 2014-01-29 | due-trials |
| Reported results | 2010-020911-35 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in T... | 2013-09-19 | due-trials |
| Reported results | 2010-021925-12 | FINITE CHB - First investigation in stopping TDF treatment after long term virologic suppression in HBeAg-negative Chronic Hepatitis B | 2016-08-23 | due-trials |
| Reported results | 2010-022155-33 | A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non- Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents Studio di fase 2 per valutare l'ef... | 2018-05-16 | due-trials |
| Reported results | 2010-023178-37 | A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Ril... | 2014-12-22 | due-trials |
| Reported results Terminated | 2010-023952-10 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) ... | 2013-08-15 | due-trials |
| Reported results | 2010-023959-28 | A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in... | 2013-07-16 | due-trials |
| Reported results | 2010-024007-27 | A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen... | 2014-02-04 | due-trials |
| Reported results | 2010-024586-45 | A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon ?-2a (Pegasys®) ver... | 2015-07-17 | due-trials |
| Reported results | 2011-000456-42 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS 5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatmen... | 2013-06-14 | due-trials |
| Reported results | 2011-000488-29 | A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients with Mild to Moderate Renal Impairment | 2015-02-16 | due-trials |
| Completed, but no date, and reported results | 2011-000944-43 | A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection | bad-data | |
| Reported results | 2011-000945-19 | A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection | 2017-11-30 | due-trials |
| Reported results | 2011-000946-39 | A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection | 2018-04-09 | due-trials |
| Reported results | 2011-000997-77 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects with Type 2 Diabetes Mellitus | 2013-08-29 | due-trials |
| Reported results | 2011-001134-42 | A phase 2, proof of concept, randomised, placebo-controlled, parallel group study to evaluate the effect of ranolazine and dronedarone when given alone and in combination on atrial fibrillation burden... | 2014-03-10 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-001255-36 | Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients with Cystic Fib... | 2013-06-20 | bad-data |
| Trial is partly outside EEC, and reported results | 2011-001362-18 | Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children with Cystic Fibrosis (CF) and Chroni... | 2013-04-03 | bad-data |
| Reported results | 2011-001516-54 | A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging Stud... | 2012-09-27 | due-trials |
| Reported results | 2011-002273-29 | A Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects with Chronic Stable Angina and Coronary Artery Disease with a History of Type 2 Diabetes Mellitus | 2012-10-25 | due-trials |
| Reported results | 2011-002507-15 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous ... | 2015-02-09 | due-trials |
| Reported results | 2011-002748-28 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects w... | 2013-07-29 | due-trials |
| Reported results | 2011-002931-25 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects with Type 2 Diabetes Mellitus | 2013-10-21 | due-trials |
| Reported results | 2011-003753-26 | A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma | 2015-02-11 | due-trials |
| Reported results Terminated | 2011-003754-61 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenoca... | 2015-01-22 | due-trials |
| Reported results | 2011-004420-35 | A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects | 2014-10-06 | due-trials |
| Reported results | 2011-004483-30 | A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to... | 2014-12-16 | due-trials |
| Reported results | 2011-004963-56 | A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to th... | 2014-12-01 | due-trials |
| Reported results | 2011-005055-14 | A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in... | 2013-04-08 | due-trials |
| Reported results | 2011-005180-24 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia | 2014-05-07 | due-trials |
| Reported results | 2011-006292-20 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymp... | 2019-06-28 | due-trials |
| Reported results | 2011-006293-72 | A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS 1101) for Previously Treated Chronic Lymphocytic Leukemia A Comp... | 2018-06-29 | due-trials |
| Reported results | 2012-000571-16 | An Open-Label Study of GS-7977 + Ribavirin with or without Peginterferon Alfa-2a in Subjects with Chronic HCV Infection who Participated in Prior Gilead HCV Studies. | 2014-12-22 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-000586-20 | A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection | bad-data | |
| Completed, but no date, and reported results | 2012-000637-39 | An Open-Label Study to Explore the Clinical Efficacy of GS-7977 with Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant Ensayo abierto para explo... | bad-data | |
| Reported results | 2012-001236-65 | A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | 2018-08-15 | due-trials |
| Reported results | 2012-001259-37 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects with Type 2 Diabetes Mellitus. | 2013-10-01 | due-trials |
| Reported results Terminated | 2012-001571-36 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) | 2016-02-23 | due-trials |
| Reported results | 2012-001942-16 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subje... | 2014-01-08 | due-trials |
| Reported results | 2012-002413-19 | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected with Respiratory Syncytial Virus (RSV-A Memph... | 2013-06-27 | due-trials |
| Reported results | 2012-002417-19 | A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 weeks in Subjects with Recurrent Chronic HCV Post Liver Transplant | 2014-08-20 | due-trials |
| Completed, but no date, and reported results | 2012-002457-29 | A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 24 weeks in Patients Infected with Chronic HCV with Cirrhosis and ... | bad-data | |
| Reported results | 2012-002473-61 | A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with ... | 2016-08-24 | due-trials |
| Reported results | 2012-002488-88 | A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with... | 2016-12-29 | due-trials |
| Reported results | 2012-002489-11 | A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with... | 2017-01-03 | due-trials |
| Reported results | 2012-003387-43 | A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects wit... | 2014-04-30 | due-trials |
| Reported results | 2012-003655-11 | A multicenter, open-label, long-term follow-up safety and efficacy study of GLPG0634 treatment in subjects with moderately to severely active rheumatoid arthritis | 2023-01-19 | due-trials |
| Reported results | 2012-003708-11 | A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... | 2018-09-06 | due-trials |
| Reported results | 2012-004013-13 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymph... | 2016-06-18 | due-trials |
| Reported results | 2012-004034-42 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent ... | 2016-05-17 | due-trials |
| Reported results | 2012-004154-28 | A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infe... | 2014-07-10 | due-trials |
| Reported results | 2012-004458-27 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Diso... | 2017-09-29 | due-trials |
| Reported results | 2012-005114-20 | A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subj... | 2020-04-01 | due-trials |
| Reported results | 2013-000102-37 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Diso... | 2018-10-03 | due-trials |
| Reported results | 2013-000516-25 | A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment | 2018-07-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000626-63 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Ne... | 2022-08-19 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2013-000636-10 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Po... | 2022-10-13 | bad-data |
| Trial is partly outside EEC | 2013-001402-28 | A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Em... | bad-data | |
| Trial is partly outside EEC, and reported results | 2013-001969-16 | A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) ... | 2017-10-27 | bad-data |
| Reported results | 2013-002296-17 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks with Ribavirin or for 24 ... | 2014-11-12 | due-trials |
| Reported results | 2013-002641-11 | A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or ... | 2016-07-07 | due-trials |
| Reported results | 2013-002707-33 | A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocyth... | 2019-05-02 | due-trials |
| Trial is outside EEC, and reported results | 2013-002780-26 | A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-... | bad-data | |
| Reported results | 2013-002802-30 | A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have ... | 2015-08-27 | due-trials |
| Reported results | 2013-002830-19 | A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafena... | 2017-07-31 | due-trials |
| Reported results | 2013-002897-30 | A Phase 2b Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects with Renal Insufficiency | 2017-10-19 | due-trials |
| Reported results | 2013-003313-17 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocyt... | 2016-06-16 | due-trials |
| Reported results | 2013-003314-41 | A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion | 2016-05-17 | due-trials |
| Reported results | 2013-003978-27 | A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genot... | 2015-02-17 | due-trials |
| Reported results Terminated | 2013-004105-11 | A Phase 2, Open-label, Randomized Study to Evaluate Safety and Efficacy of Momelotinib in Subjects with Polycythemia Vera or Essential Thrombocythemia | 2015-05-01 | due-trials |
| Reported results | 2013-004429-97 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy | 2017-02-17 | due-trials |
| Reported results | 2013-004430-15 | A Phase 2, Double-Blind, Randomized, Placebo Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibr... | 2016-10-14 | due-trials |
| Reported results | 2013-004476-36 | Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects with Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, Post essential Thrombocythemia Myelofibrosis,... | 2018-12-06 | due-trials |
| Reported results | 2013-004551-20 | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untre... | 2016-05-13 | due-trials |
| Reported results | 2013-005007-13 | A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosi... | 2019-04-25 | due-trials |
| Reported results | 2013-005138-39 | A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF | 2019-03-01 | due-trials |
| Reported results | 2013-005343-82 | An Expanded Access Protocol for Idelalisib in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia | 2017-08-15 | due-trials |
| Reported results Terminated | 2014-000042-30 | A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT-3 Syndrome | 2017-02-15 | due-trials |
| Completed, but no date, and reported results | 2014-001011-39 | A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B an... | bad-data | |
| Reported results | 2014-001245-24 | An open-Label, multicenter study to evaluate the efficacy and safety of sofosbuvir/ledipasvir fixed-dose combination ± ribavirin for 12 or 24 weeks in chronic genotype 1 HCV infected subjects who part... | 2015-11-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-001249-26 | A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Spo... | 2021-12-31 | bad-data |
| Reported results | 2014-001400-22 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects with Chronic Hepatitis B | 2016-10-20 | due-trials |
| Reported results | 2014-001682-27 | A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects... | 2015-12-15 | due-trials |
| Reported results | 2014-001683-35 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV | 2015-09-23 | due-trials |
| Reported results | 2014-002095-93 | A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus... | 2016-02-17 | due-trials |
| Reported results | 2014-002121-35 | A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients with Chronic H... | 2016-06-16 | due-trials |
| Reported results | 2014-002131-34 | A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension | 2016-12-13 | due-trials |
| Reported results | 2014-002137-58 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory ... | 2017-04-12 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-002283-32 | A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infecti... | 2018-09-13 | bad-data |
| Reported results | 2014-002474-36 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) R... | 2017-07-14 | due-trials |
| Reported results | 2014-002475-29 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) R... | 2017-04-17 | due-trials |
| Trial is outside EEC, and reported results | 2014-002673-11 | A Phase 2/3, Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents | bad-data | |
| Trial is partly outside EEC, and reported results | 2014-003578-17 | A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- RBV in Adolescents and Children with Chronic HCV-Infec... | 2018-08-24 | bad-data |
| Reported results | 2014-003898-42 | An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection | 2016-06-15 | due-trials |
| Reported results | 2014-004480-20 | A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Do... | 2017-04-10 | due-trials |
| Reported results | 2014-004545-27 | A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Su... | 2019-01-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-004674-42 | A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead Sponsored Chronic Hepatitis C Infection Trials | 2023-01-06 | bad-data |
| Reported results | 2014-004779-21 | A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtric... | 2019-01-02 | due-trials |
| Reported results | 2014-004812-12 | Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Subjects with Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chro... | 2016-01-08 | due-trials |
| Reported results | 2014-004939-39 | Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicit... | 2018-04-18 | due-trials |
| Reported results | 2014-005217-24 | A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerat... | 2016-11-16 | due-trials |
| Trial is outside EEC, and reported results | 2015-000304-26 | A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa with Continued Access to Emtricitabine. | bad-data | |
| Trial is outside EEC, and reported results | 2015-000313-40 | A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 In... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2015-000366-66 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | 2022-09-27 | bad-data |
| Trial is outside EEC, and reported results | 2015-000395-97 | A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis, Mild Lung Disease, and P. aeruginosa (AIR-... | bad-data | |
| Trial is outside EEC, and reported results | 2015-000396-26 | Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disease ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-000397-36 | Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for... | bad-data | |
| Trial is outside EEC, and reported results | 2015-000398-11 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-000466-57 | A Phase 1, Single-dose Study to Evaluate the Relative Bioavailability of Cobicistat (COBI) Age-Appropriate Pediatric Tablet Formulations Compared with Adult COBI 150-mg Tablets in Healthy Adult Volunt... | bad-data | |
| Reported results | 2015-000690-13 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults with Chronic HCV Infection. | 2016-06-30 | due-trials |
| Trial is outside EEC, and reported results | 2015-000725-37 | A Phase 1 Study to Evaluate the Bioavailability of Boosted Age-Appropriate Pediatric Elvitegravir (EVG) Tablet or Suspension Formulation Compared with Adult EVG 150 mg Tablets in Healthy Adult Volunte... | bad-data | |
| Trial is outside EEC, and reported results | 2015-000727-85 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents | bad-data | |
| Reported results | 2015-000871-28 | A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC | 2019-03-13 | due-trials |
| Completed, but no date, and reported results Terminated | 2015-001050-16 | A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects with Chronic Hepatitis B Infection. Studio di registro di follow-up a lungo termine di soggetti trattati i... | bad-data | |
| Reported results | 2015-001249-10 | A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Crohn's Disease Studio multic... | 2016-12-22 | due-trials |
| Trial is partly outside EEC, and reported results | 2015-001339-19 | A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Re... | bad-data | |
| Reported results | 2015-001526-42 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroes... | 2019-05-15 | due-trials |
| Reported results | 2015-002017-30 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of ... | 2019-05-03 | due-trials |
| Reported results | 2015-002192-23 | A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects with Cystic Fibrosis | 2017-07-21 | due-trials |
| Reported results | 2015-002287-16 | A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) Infection | 2017-09-27 | due-trials |
| Reported results | 2015-002710-74 | A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infect... | 2019-07-11 | due-trials |
| Reported results | 2015-002711-15 | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Antiretroviral Agent to the Elvitegravi... | 2018-01-24 | due-trials |
| Reported results | 2015-002712-32 | A Phase 3b, Randomized, Open-Label Study to Evaluate Switching from a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF)... | 2018-03-21 | due-trials |
| Reported results | 2015-002713-30 | A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis | 2019-10-15 | due-trials |
| Reported results | 2015-002731-17 | A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (ENTO [GS-9973]) combined with Vincristine (VCR) in Adult Subjects with Relapsed or Re... | 2017-06-22 | due-trials |
| Reported results | 2015-002996-12 | A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for... | 2017-01-02 | due-trials |
| Reported results | 2015-003001-42 | A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) infection | 2017-09-13 | due-trials |
| Reported results | 2015-003167-10 | A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for... | 2017-01-18 | due-trials |
| Reported results | 2015-003455-21 | A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direc... | 2017-06-21 | due-trials |
| Reported results | 2015-003460-36 | A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatas... | 2017-01-11 | due-trials |
| Trial is outside EEC, and reported results | 2015-003570-32 | A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Granules Formulation of Ledipasvir/Sofosbuvir in Healthy Adult Subjects | bad-data | |
| Exempt, with results | 2015-003741-26 | A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-5829 as a Single Agent and In Combination with Enzalutamide in Subjects with Metastatic Castrate-Re... | 2019-09-03 | not-yet-due |
| Reported results | 2015-003909-42 | A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib with and without Obinutuzumab in Subjects with Ch... | 2021-01-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-003988-10 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected... | 2021-07-05 | bad-data |
| Reported results | 2015-004011-20 | A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lam... | 2019-12-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-004024-54 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral T... | 2021-07-02 | bad-data |
| Reported results | 2015-004025-14 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9... | 2019-10-23 | due-trials |
| Reported results Terminated | 2015-004572-30 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First... | 2017-12-14 | due-trials |
| Reported results | 2015-005766-39 | An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3Kδ Inhibitor, GS-9820 | 2017-12-28 | due-trials |
| Reported results | 2016-000416-15 | A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have Received a Liver Transplan... | 2017-07-28 | due-trials |
| Reported results | 2016-000417-73 | A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects... | 2017-10-27 | due-trials |
| Reported results | 2016-000568-41 | A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Sub... | 2019-06-20 | due-trials |
| Reported results | 2016-000569-21 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-... | 2018-06-26 | due-trials |
| Reported results | 2016-000570-37 | A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexa... | 2019-05-08 | due-trials |
| Trial is partly outside EEC | 2016-000785-37 | A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection | bad-data | |
| Reported results | 2016-000821-37 | A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepa... | 2018-05-25 | due-trials |
| Reported results | 2016-000897-39 | Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects with Moderate to Severe Rheumatoid Arthritis. | 2017-08-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-001367-36 | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Sev... | 2022-11-11 | bad-data |
| Reported results | 2016-001392-78 | Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to ... | 2020-03-31 | due-trials |
| Ongoing | 2016-001399-31 | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men a... | not-yet-due | |
| Reported results | 2016-001402-41 | A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesopha... | 2019-08-23 | due-trials |
| Reported results | 2016-001496-75 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects with Active Rheumatoid Arthritis on Ba... | 2017-09-20 | due-trials |
| Trial is outside EEC | 2016-002345-39 | A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected ... | bad-data | |
| Exempt, with results | 2016-002365-63 | A Phase 1b Study Followed by an Open label, Parallel, Randomized Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of GS-5829 in Combination with Exemestane or Fulvestrant Comparing with ... | 2018-07-19 | not-yet-due |
| Reported results | 2016-002442-23 | A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis | 2020-05-18 | due-trials |
| Reported results | 2016-002443-42 | A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis | 2019-09-04 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-002446-23 | A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection | 2020-02-26 | bad-data |
| Reported results | 2016-002496-10 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH) | 2018-01-09 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-002749-42 | Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (A... | 2021-09-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-002763-34 | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease Studio di estensione a lungo termine per la valutazione della sicurezza di Filgotinib in soggetti c... | 2023-09-05 | bad-data |
| Ongoing | 2016-002765-58 | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | not-yet-due | |
| Reported results | 2016-002768-15 | A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib with and without Obinutuzumab in Subjects with ... | 2020-10-01 | due-trials |
| Reported results | 2016-003066-10 | A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection and Chil... | 2018-12-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003153-15 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn¿s Disease Studio di fase II, in doppio ... | 2021-02-17 | bad-data |
| Reported results | 2016-003179-23 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn¿s Disease (SBCD) Studio di fase II, in doppio ci... | 2020-07-20 | due-trials |
| Reported results | 2016-003353-16 | A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML) | 2019-02-21 | due-trials |
| Exempt | 2016-003408-29 | A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma | not-yet-due | |
| Reported results | 2016-003489-25 | A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Re... | 2019-02-13 | due-trials |
| Reported results | 2016-003558-34 | A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren’s Syndrome | 2019-10-02 | due-trials |
| Reported results | 2016-003625-42 | A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Disea... | 2018-11-07 | due-trials |
| Ongoing | 2016-003630-25 | A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis | not-yet-due | |
| Reported results | 2016-003632-20 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Ch... | 2020-01-30 | due-trials |
| Reported results | 2016-004148-13 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) | 2019-04-30 | due-trials |
| Reported results | 2016-004374-18 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. | 2019-06-12 | due-trials |
| Reported results | 2016-004625-16 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Viro... | 2020-09-04 | due-trials |
| Reported results | 2017-000179-98 | An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects who Participated in a Prior Gilead-Sponsored HCV Treatmen... | 2018-03-19 | due-trials |
| Reported results | 2017-000308-17 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Diso... | 2021-02-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-000402-38 | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease | 2023-10-24 | bad-data |
| Reported results Terminated | 2017-001468-39 | Phase 1b trial evaluating idelalisib in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma or mediastinal B-cell lymphoma in combination with RICE | 2018-11-16 | due-trials |
| Other | 2017-001485-17 | A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non-Infectious Uveitis | not-yet-due | |
| Reported results Terminated | 2017-003055-30 | Immune Response to Influenza Vaccine in Subjects with B-cell Malignancies Treated with Idelalisib | 2019-10-09 | due-trials |
| Reported results | 2017-003428-61 | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/ Cobicistat/ Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate ... | 2020-05-29 | due-trials |
| Trial is outside EEC, and reported results | 2017-003956-22 | A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Oral Granule Formulation of Ledipasvir/Sofosbuvir in Healthy Adult Subjects | bad-data | |
| Trial is outside EEC, and reported results | 2017-004044-37 | A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Oral Granule Formulation of SOF/VEL in Healthy Adult Subjects. | bad-data | |
| Ongoing | 2017-004350-42 | Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | not-yet-due | |
| Reported results | 2018-000480-87 | A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed Dose Combination in Adolescents and Childre... | 2020-02-19 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-000926-79 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir... | 2024-03-07 | bad-data |
| Other | 2018-001167-23 | A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy Étude de phase II en ouvert de l’IMMU 132 da... | not-yet-due | |
| Trial is outside EEC, and reported results | 2018-003741-42 | A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Undergoin... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2018-003951-39 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disea... | 2020-01-06 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-004201-33 | Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negativ... | 2023-10-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-000204-14 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis. | 2022-12-23 | bad-data |
| Other | 2019-000579-18 | A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors | not-yet-due | |
| Completed, report not yet due | 2019-001213-17 | "A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients with Chronic Hepatitis Delta" "Studio multicentrico, randomizzato, in aperto, ... | 2024-08-08 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2019-001430-33 | A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis | 2021-12-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-001485-15 | A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta | 2022-09-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-001996-35 | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic DMA... | 2021-05-11 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-002021-29 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intol... | 2021-05-11 | bad-data |
| Trial is outside EEC, and reported results | 2019-003269-16 | A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability of a Pediatric Oral Granule Formulation of Tenofovir Alafenamide in Healthy Adults | bad-data | |
| Ongoing | 2019-003814-16 | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-003958-86 | Study of Females Exposed to Eleclazine | 2024-01-31 | bad-data |
| Exempt, with results | 2019-004605-27 | A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects with Advanced Solid Tumors | 2021-03-30 | not-yet-due |
| Other | 2019-004868-22 | Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan. | not-yet-due | |
| Reported results | 2020-000841-15 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 | 2020-06-30 | due-trials |
| Reported results | 2020-000842-32 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment | 2020-06-26 | due-trials |
| Reported results | 2020-001453-49 | Expanded Access Treatment Protocol: Remdesivir (RDV;GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection- COVID-19 Protocolo del tratamiento de acceso expandido: Remdesivir (RDV;GS-5734) para el... | 2020-09-23 | due-trials |
| Ongoing, reported early | 2020-001803-17 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19 | not-yet-due | |
| Ongoing | 2020-002964-29 | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer Studio randomi... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-003510-12 | A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting | 2021-05-06 | bad-data |
| Completed, report not yet due | 2020-003949-11 | A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or Inte... | 2024-03-25 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2020-004287-26 | ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patient with Higher Risk Myelodysplastic ... | 2023-07-18 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-005265-14 | A Phase 2 Multi-Arm Study of Magrolimab in Patients with Solid Tumors | 2024-10-01 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-005416-22 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are... | 2022-05-24 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-005708-20 | A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma | 2024-10-02 | bad-data |
| Trial is outside EEC, and reported results | 2021-000436-62 | A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability and Food Effect of a Pediatric Tablet for Oral Suspension of Bictegravir/Emtricitabine/Tenofovir Alafenamide and the Bi... | bad-data | |
| Completed, report not yet due | 2021-000672-11 | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | 2024-07-19 | not-yet-due |
| Trial is outside EEC, and reported results | 2021-001073-23 | A Phase 1b, Open-label study to Evaluate the PK, Safety and Efficacy of B/F/TAF in HIV-1 infected, Virologically Suppressed, Pregnant Women in their Second and Third Trimesters | bad-data | |
| Ongoing | 2021-001445-12 | A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in... | not-yet-due | |
| Completed, but no date | 2021-001798-21 | A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma Víceramenná studie fáze 2 hodnotící kombinace magrolimabu u pacientů s relabujícím/refrakt... | bad-data | |
| Completed, report not yet due | 2021-003434-36 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previou... | 2024-04-11 | not-yet-due |
| Other | 2021-003578-30 | Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or A... | not-yet-due | |
| Other | 2021-004280-27 | An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Ge... | not-yet-due | |
| Ongoing | 2021-005546-15 | Simplified model of linkage & retention to care, using a mobile unit and a same-day test & treat approach among excluded population. The SIMPLIFIED Study Modelo simplificado de acceso y retención a... | not-yet-due | |
| Other | 2021-005742-14 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inop... | not-yet-due | |
| Ongoing | 2021-005743-79 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negativ... | not-yet-due | |
| Other | 2022-000578-25 | A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2022-002741-18 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression | 2023-11-07 | bad-data |